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The scavenger receptor C-type lectin (SRCL) is a glycan-
binding receptor that has the capacity to mediate endo-
cytosis of glycoproteins carrying terminal Lewisx groups
(Gal1–4(Fuc1–3)GlcNAc). A screen for glycoprotein ligands
for SRCL using affinity chromatography on immobilized SRCL
followed by mass spectrometry-based proteomic analysis
revealed that soluble glycoproteins from secondary granules of
neutrophils, including lactoferrin and matrix metalloprote-
inases 8 and 9, are major ligands. Binding competition and sur-
face plasmon resonance analysis showed affinities in the low
micromolar range. Comparison of SRCL binding to neutrophil
and milk lactoferrin indicates that the binding is dependent on
cell-specific glycosylation in the neutrophils, as themilk formof
the glycoprotein is a much poorer ligand. Binding to neutrophil
glycoproteins is fucose-dependent, and mass spectrometry-
based glycomic analysis of neutrophil and milk lactoferrin was
used to establish a correlation between high affinity binding to
SRCL and the presence of multiple clustered terminal Lewisx
groups on a heterogeneous mixture of branched glycans, some
with poly N-acetyllactosamine extensions. The ability of SRCL
tomediate uptake of neutrophil lactoferrinwas confirmedusing
fibroblasts transfected with SRCL. The common presence of
Lewisx groups in granule protein glycans can thus target granule
proteins for clearance by SRCL. PCRand immunohistochemical
analysis confirm that SRCL is widely expressed on endothelial
cells and thus represents a distributed system that could scav-
enge released neutrophil glycoproteins both locally at sites of
inflammation or systemically when they are released in the
circulation.
The scavenger receptor C-type lectin (SRCL,2 also desig-
nated collectin P1) is an endothelial cell surface receptor able to
mediate endocytosis of several classes of ligands (1–3). The
extracellular portion of the receptor consists of three distinct
regions as follows: a coiled coil of -helices450 Å in length; a
collagen-like region of a similar length; and a globular C-termi-
nal C-type carbohydrate-recognition domain (CRD). These
regions are predicted to be linked by flexible joints (4).
Although the first two types of domains are found in other class
A scavenger receptors, SRCL is the only example of a scaven-
ger-type receptor in this class that contains a C-type CRD (5).
In functional terms, the -helical region in SRCL probably
forms a stalk projecting from the cell surface, and studies with
truncated forms of the receptor indicate that, as with other
scavenger receptors, yeast and other microbes bind to the col-
lagen-like domains, probably through regions containing clus-
ters of positively charged amino acid residues (1). The CRD
shows high selectivity for glycans terminating with the Lewisx
trisaccharide (Gal1–4(Fuc1–3)GlcNAc and recognizes
Lewisx-containing glycoconjugates (6), but no physiological
ligands for the receptor have been reported. The endothelial
expression of SRCL suggests that the receptor could be
involved in mediating adhesion of circulating cells to the endo-
thelium during leukocyte extravasation, a function analogous
to that of the selectin family of C-type lectins (7). Consistent
with a role for SRCL in cell adhesion, the Lewisx structure is
found on the surfaces of leukocytes and has been implicated in
neutrophil adhesion (8). It has also been proposed that SRCL
mediates adhesion of Lewisx-expressing cancer cells to endo-
thelium (9).However, a role of SRCL in cell adhesion remains to
be established definitively.
The endocytic activity of SRCL supports the alternative sug-
gestion that this receptor may be involved in uptake and degra-
dation of glycoproteins (6). Several other receptors that contain
C-type CRDs as well as other types of sugar-binding domains
have been implicated in glycoprotein turnover (10). The roles of
the mannose receptor on macrophages in the clearance of gly-
coprotein hormones tagged with GalNAc-4-SO4 and released
lysosomal enzymes bearing high mannose oligosaccharides
have been particularly well characterized (11, 12), and the
importance of the hepatic asialoglycoprotein receptor in clear-
ance of specific subclasses of serum glycoproteins has been
extensively studied (13, 14).
In the studies reported here, the function of SRCL was
probed by identifying specific glycoprotein ligands associated
with cells in the blood. The predominant SRCL ligands in neu-
trophils were found to be soluble granule proteins rather than
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cell surface proteins, suggesting that a major role for SRCL is
likely to be in the clearance of glycoproteins released at sites of
inflammation, which may be tagged with Lewisx epitopes to
facilitate their uptake after release.
EXPERIMENTAL PROCEDURES
Generation of Biotin-tagged CRD of SRCL—The coding
sequence for the biotinylation tag Gly-Leu-Asn-Asp-Ile-Phe-
Glu-Ala-Gln-Lys-Ile-Glu-Trp-His-Glu, in which the lysine res-
idue is a target for biotinylation (15), was added to the C termi-
nus of the CRD in the expression vector pT5T (16). Escherichia
coli strain BL21/DE3 cells containing this expression plasmid as
well as a plasmid containing the chloramphenicol resistance
gene and the birA biotin ligase gene (17) were grown in 1-liter
batches, and inclusion bodies were isolated and dissolved in
guanidine as described previously for preparation of other bio-
tin-tagged CRDs (18). Following renaturation by dilution into 4
volumes of loading buffer (0.5 M NaCl, 25 mM Tris-Cl, pH 7.8,
25 mM CaCl2) and dialysis against three changes of the same
buffer, the tagged CRD was isolated following the procedure
developed for the untagged CRD (6).
Detection of SRCL Expression by PCR—PCR-ready first
strand cDNAs for a range of tissues were obtained from Bio-
Chain. PCR was performed using the Advantage 2 polymerase
kit (Takara) using the standard conditions with the following
primers: gtgcccctggccctgcagaatgagccaacc (forward) and aattt-
gctcatgtgatcccatcacagtccg (reverse). After the initial incubation
at 95 °C for 1min, cycles of 30 s at 95 °C and 1min at 65 °Cwere
performed. Productswere resolved on a 2% agarose gel contain-
ing SYBR-Safe (Invitrogen) to visualize DNA.
Gels and Blotting—An aliquot (100 g) of the extracellular
domain of SRCL purified from transfected Chinese hamster
ovary cells (6) was resuspended in 500 l of 25 mM Bicine, pH
8.5, 0.5 MNaCl, 25mMCaCl2 and incubated for 20min at room
temperature with 250 Ci of 125I-Bolton-Hunter Reagent
(PerkinElmer Life Sciences). Labeled protein was applied to a
1-ml column of galactose-Sepharose that was washed with four
1-ml aliquots of loading buffer (0.5 M NaCl, 25 mM Tris-Cl, pH
7.8, 25mMCaCl2) and elutedwith five 0.5-ml aliquots of eluting
buffer (0.5 M NaCl, 25 mM Tris-Cl, pH 7.8, 2.5 mM EDTA).
Streptavidin-conjugated bacterial alkaline phosphatase (100
g, Sigma) was incubated with a large excess of purified biotin-
ylated CRD of SRCL in loading buffer at 4 °C overnight with
rotary agitation. The resulting complexes were repurified on a
1-ml column of galactose-Sepharose in the same way. Elution
fractions containing SRCL-streptavidin complexes (SRCL con-
jugated to alkaline phosphatase) were identified by SDS-PAGE.
SDS-polyacrylamide gels were run in the buffer system of
Laemmli. All gels contained 17.5% acrylamide unless otherwise
indicated, and blotting was performed on nitrocellulose (19).
Blots were blockedwith 2% bovine hemoglobin in low salt load-
ing buffer (150 mMNaCl, 25 mM Tris-Cl, pH 7.8, 25 mM CaCl2)
for 60 min at room temperature with agitation, followed by
radiolabeled or alkaline phosphatase-tagged receptor in this
same hemoglobin solution for 90 min. After four 10-min
washes with low salt loading buffer, radioactivity on blots was
detectedwith a phosphorimager fromGEHealthcare, and alka-
line phosphate was detected with 5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium substrate (Calbiochem).
Immunoblotting was performed using rabbit polyclonal anti-
bodies to pan-CEACAM (Abcam) at a 1:500 dilution fol-
lowed by visualization using alkaline phosphatase-conju-
gated protein A.
Purification of Ligands fromHumanGranulocytes by Affinity
Chromatography—An SRCL affinity column was created by
passing 5 mg of biotinylated CRD of SRCL in eluting buffer
over a 2-ml column of avidin-agarose (Pierce) pre-rinsed with
the same buffer. The columnwas washed extensively with elut-
ing buffer followed by loading buffer. A sample of the washed
resin was analyzed by SDS-PAGE to confirm binding of the
CRD to the resin.
Leukocytes were isolated from50ml of fresh human blood
containing 1.5 mg/ml EDTA as an anticoagulant. Granulocytes
were isolated by centrifugation through Ficoll-Paque PLUS
(d  1.077 g/cm3; Amersham Biosciences) followed by lysis of
erythrocytes in ammonium bicarbonate (20). Granulocytes
were lysed by sonication in low salt loading buffer containing
1%Triton X-100 and a protease inhibitormixture (Calbiochem
protease inhibitor mixture set 1), incubated for 30 min on ice,
and centrifuged at 4,000 rpm for 10min in an Eppendorf 5810R
centrifuge. The supernatant was passed over the SRCL affinity
column, which was washed with five 1-ml aliquots of low salt
loading buffer containing 0.1% Triton X-100 and eluted with
five 1-ml aliquots of low salt eluting buffer containing 0.1%
Triton X-100. For repurification of ligands, the elution frac-
tions were pooled, adjusted to 25 mM CaCl2, and applied to the
column again. The column was washed and eluted as before.
Proteomic Analysis by Mass Spectrometry—Affinity-purified
proteins were resolved by SDS-PAGE and stained with Coo-
massie Blue. Bands for proteomic analysis were excised from
the gel, reduced and carboxymethylated, digested with trypsin,
and subjected to MALDI mass spectrometry (21). MS and
MS/MS data were used to search 17,869 human entries in
release 54.6 of the SwissProt data base with version 2.2 of the
Mascot data base search algorithm. For the search, peptide
masses were fixed as monoisotopic; the mass tolerance was set
at 75 ppm for precursor ions and 0.1 Da for fragment ions;
partial carboxymethylation of cysteine residues and partial oxi-
dation of methionine residues were considered, and up to one
missed trypsin cleavage site was allowed. Proteinmatches from
both MS and MS/MS data were used to generate probability-
based Mowse protein scores. Scores greater than 55 were con-
sidered significant (p 0.05) (22). Additional information, such
as agreement between molecular weight of the tentatively
matched protein and mobility on the SDS-polyacrylamide gel,
was used to evaluate lower confidence matches, where the
number of peptides detected might be low because the protein
is scarce or small, has few trypsin cleavage sites, or is post-
translationally modified. For instances in which the mass spec-
trometry results suggested that a single band contained more
than one protein, it was ensured that each protein match was
derived from nonoverlapping sets of detected peptides.
Fucosidase Treatment of Neutrophil Glycoproteins—Lacto-
ferrin from human neutrophils (Sigma) was dialyzed against
water and lyophilized. An aliquot (5 g) was digested with 1
unit/ml bovine kidney -L-fucosidase (Sigma) at 37 °C for 48 h
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in 50 l of 100 mM sodium citrate, pH 5.6. Samples equivalent
to 1 g of lactoferrin were analyzed by gel electrophoresis and
blotting. Matrix metalloproteinase (MMP) 9 from human neu-
trophils (Calbiochem), at a concentration of 100g/ml in 50l
in 50 mM Tris-Cl, pH 7.0, 200 mM NaCl, 5 mM CaCl2, 1 M
ZnCl2, 0.05% BRIJ 35 detergent, 0.05% sodium azide, was sup-
plemented with 12.5 l of 1 M sodium citrate, pH 5.6. A 25-l
aliquot of this solution (2 g of protein) was incubated for 24 h
at 37 °C with 5 l of fucosidase solution.
Binding Assays—Solid phase binding assays were performed
as described previously (6). Surface plasmon resonance mea-
surements were made using a BIAcore 3000 instrument with
BIAcore 3000 Control software and BIAevaluation software.
Neutrophil lactoferrin was coupled to activated CM5 sensor
chips (BIAcore) by flowing a 50 g/ml solution of protein in 10
mM sodium acetate, pH 5.0, over the chip for 10 min at a flow
rate of 10l/min. CRD of SRCLwas resuspended at 1mg/ml in
10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM CaCl2, 0.005% P20
detergent, and serial dilutions were prepared using the same
buffer, with 1 g/ml as the lowest concentration. The sensor
chipwas regenerated between samples using 10mMHEPES, pH
7.4, 150 mM NaCl, 3 mM EDTA, 0.005% P20 detergent. The
response values after 80 s of binding were fitted to a direct
binding equation using SigmaPlot software.
Glycan Analysis—Purified lactoferrin derived from milk or
neutrophils (0.5 mg) was precipitated with trichloroacetic
acid and resuspended in 25 l of 8 M urea, 10 mM HEPES, pH
8.0. The protein was digested at 37 °C overnight with L-1-tosyl-
amido-2-phenylethyl chloromethyl ketone-treated trypsin
from bovine pancreas (Sigma) at a final concentration of 50
g/ml in a final volume of 250 l of 50 mM ammonium bicar-
bonate, pH 8.4. Isolation of glycopeptides, release of glycans,
and permethylation were performed as described previously
(23). The data presented were obtained from the 50% acetoni-
trile fraction of permethylated glycans, except that data for the
35% acetonitrile fraction are shown in supplemental Fig. S6A.
The fractionated glycans were dissolved in 10 l of methanol,
and a 1-l aliquot of dissolved sample was mixed with 1 l of
2,5-dihydroxybenzoic acid matrix solution (20 mg/ml in 70%
methanol). Two aliquots of 0.5 l were spotted onto a target
plate and dried under vacuum. MALDI MS and MS/MS data
were acquired using anAppliedBiosystems 4800MALDI-time-
of-flight/time-of-flight mass spectrometer. The collision
energy was set to 1 kV for MS/MS fragmentation, and argon
was used as collision gas. The Calmix 4700 calibration standard
kit (Applied Biosystems) was used as the external calibrant for
the MS mode and [Glu1] fibrinopeptide B human (Sigma) was
used as an external calibrant for the MS/MS mode. MS and
MS/MS data were processed using Data Explorer 4.9 software
(Applied Biosystems). The proposed assignments for the
selected peakswere based on 12C isotopic composition together
with knowledge of the biosynthetic pathways with the aid of the
glycobioinformatics tool GlycoWorkbench (24). The proposed
structures were then confirmed by MS/MS experiments.
Aliquots of underivatized N-glycans derived from 50 g of
neutrophil lactoferrin were subjected to chemical and enzy-
matic degradation. Sialidase digestion was performed in 200 l
of 50mM sodiumacetate, pH 5.5, with 170milliunits of sialidase
A from Arthrobacter ureafaciens (Glyko) for 24 h at 37 °C.
Digestion with endo--galactosidase from Escherichia freundii
(EC 3.2.1.103; Glyko) was carried out in 200 l of 100 mM
sodium acetate, pH 5.8, at 37 °C for 48 h, with aliquots of
enzyme (20 milliunits) added at 0 and 24 h. All digested
samples were lyophilized, permethylated, and purified on a
C18 Sep-Pak (Waters). For HF treatment, dry glycans were
incubated overnight at 4 °C with 50 l of 48% HF, and the
reaction was terminated by drying under a stream of nitro-
gen before permethylation.
For linkage analysis by gas chromatography-mass spectrom-
etry, partially methylated alditol acetates were prepared, as
described previously (25), and analyzed on a Clarus 500 instru-
ment (PerkinElmer Life Sciences) fitted with an RTX-5 fused
silica capillary column, 30 m  0.32 mm (Restek Corp.). Each
samplewas dissolved in50l of hexanes (Sigma) and injected
manually (1–2 l) into the injector set at 250 °C. The oven was
initially heated at 65 °C for 1 min, following which the temper-
ature was raised linearly to 290 °C at a rate of 8 °C per min, held
at 290 °C for 5 min, and raised to 300 °C over 1 min.
Internalization of Glycoproteins by Cells—Proteins for fluo-
rescent labeling, including neutrophil lactoferrin (1 mg/ml),
BSA (5mg/ml), ovalbumin (5mg/ml, Sigma), and LNFPIII-BSA
(0.2 mg/ml, Dextra) in 100 mM Bicine, pH 9.0, 150 mM NaCl,
were reacted with fluorescein isothiocyanate (50 g/ml). Fluo-
rescein isothiocyanate was added as 5 aliquots of a stock solu-
tion at 1 mg/ml in dimethyl sulfoxide with vortexing between
each addition. Reactions were incubated at 4 °C overnight in
the dark. Excess dye was removed on a 10-ml column of Sep-
harose G-25 eluted with PBS, collecting 1-ml fractions. Dye-
containing peak fractionswere identified by eye, and samples of
all fractions were analyzed by SDS-PAGE to confirm associa-
tion of dye color with protein.
Transfected fibroblasts expressing SRCL grown on cover-
slips were incubated at 37 °C with fluorescein-labeled proteins
diluted to 1 g/ml in phenol red-free Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum.
Coverslips were washed in Dulbecco’s PBS, fixed for 15 min
with 4% paraformaldehyde in PBS, washed, and blocked for 20
min with 10% normal goat serum in PBS. Cells were incubated
for 60 min with rabbit anti-fluorescein (Abcam) at 5 g/ml
followed by 30 min with Alexa Fluor 488-labeled goat anti-
rabbit IgG (Invitrogen) at 1 g/ml in 2% normal goat serum in
PBS. Coverslips were mounted with Vectashield aqueous
mountingmedium containing DAPI (Vector Laboratories) and
sealed.
Immunofluorescence on Tissue Sections—Serial sets of tissue
array slides of formalin-fixed, paraffin-embedded human nor-
mal organs were purchased from SuperBioChips. Slides were
dried for 1 h in a 60 °C oven, deparaffinized in five changes of
xylene, and rehydrated through a graded ethanol series before
immersion in water. Heat-mediated antigen retrieval was per-
formed by incubating slides at 95–99 °C for 20 min in antigen
unmasking solution from Vector Laboratories. The TSA biotin
kit (PerkinElmer Life Sciences) was used for tyramide signal
amplification. A 15-min incubationwith 3% hydrogen peroxide
in PBS was included prior to blocking to quench endogenous
peroxidase activity. Rabbit antibodies to SRCL (23)were used at
Clearance of Neutrophil Granule Glycoproteins by SRCL
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1g/ml for 90min. Following removal of primary antibody and
washing, cells were incubated for 30 min with horseradish per-
oxidase-conjugated goat anti-rabbit IgG (Vector Laboratories)
at 1 g/ml followed by 10 min of incubation with biotinyl tyra-
mide and detection by 30 min of incubation with Alexa Fluor
488-labeled streptavidin (Invitrogen) at 2 g/ml. Images were
collected using a Nikon Eclipse E400microscope with20 and
40 objectives and a DXM1200 digital camera. Images from
the color channels were acquired as 8-bit grayscale TIFF files
with software package Lucia GF version 4.60 and converted to
merged 24-bit RGB files using Corel PhotoPaint 12.
RESULTS
Granule Proteins as Dominant Neutrophil Ligands for SRCL—
The reported expression of SRCLon endothelial cells suggested
that the receptor might mediate leukocyte adhesion through
binding to leukocyte surface glycoproteins. In an attempt to
detect potential physiological ligands for SRCL on leukocytes,
freshly isolated leukocytes were fractionated into a granulocyte
population, consisting predominantly of neutrophils with some
basophils and eosinophils, and an agranulocyte population,
containing lymphocytes and monocytes. Cell extracts from
these two populations were resolved by SDS-PAGE and blotted
onto nitrocellulose. The blots were probed with 125I-labeled
extracellular domain of SRCL, a soluble, trimeric fragment of
the receptor that exhibits highly selective and high affinity
binding to Lewisx (Fig. 1A) (6). Multiple species were detected
in the blot of a granulocyte extract, indicating that several
glycoproteins in granulocytes are recognized by SRCL. The
presence of Lewisx epitopes on these proteins would be consis-
tent with the high level of Lewisx expression in granulocytes
(26). In contrast, agranulocytes do not contain significant quan-
tities of protein recognized by SRCL, reflecting the low level of
Lewisx expression in these cells (27).
Oligomerization of SRCL is required to generate a ligand-
binding interaction of sufficiently high affinity for affinity puri-
fication of SRCL ligands. Because the naturally trimeric extra-
cellular domain of SRCL is difficult to produce in sufficient
quantity for preparation of an affinity column, artificial tetram-
ers of the bacterially produced CRD were created by binding
biotin-taggedCRDs to immobilized avidin. A subset of proteins
from solubilized granulocytes was retained on the column and
eluted with EDTA, indicating a specific interaction with the
CRD of SRCL (Fig. 1B). Probing of a blot of the fractions with
125I-SRCL confirmed that the column efficiently retains SRCL-
binding glycoproteins, with very little reactivity remaining in
the wash fractions. The efficiency and specificity of the affinity
chromatography procedure were demonstrated by the fact that
glycoproteins in the bound and eluted fractions were almost
completely retained when rerun on the affinity column (data
not shown).
Proteins present in the repurified fractionswere identified by
proteomic analysis. Following gel electrophoresis, peptides
released from individual bands by trypsin digestion were ana-
lyzed by mass spectrometry, and the resulting masses and par-
tial sequences were screened against the SwissProt data base of
human proteins. The most abundant glycoprotein identified
was lactoferrin (Fig. 2A). Other glycoproteins detected at high
levels wereM integrin,MMP-9,MMP-8, haptoglobin, neutro-
phil gelatinase-associated lipocalin, cathepsin G, and YKL40,
although the slow release of YKL40 from the SRCL affinity col-
umn in the presence of EDTA suggests that itmay be binding to
the glycans on the immobilized avidin as a result of its intrinsic
GlcNAc binding activity rather than interactionwith SRCL (28,
29). The major nonglycosylated proteins identified were the
FIGURE 1. Isolation of glycoprotein ligands for SRCL from granulocytes.
A, extracts of granulocyte and agranulocyte populations analyzed on 10%
SDS-polyacrylamidegels. Samples correspond to5105 cells.B, SDS-PAGE
of granulocyte extract fractionated by affinity chromatography on immobi-
lized CRD from SRCL. SRCL ligands were bound to the 2-ml column in the
presence of Ca2 and elutedwith EDTA. Fractions of 1ml were collected, and
aliquots of 20 l were analyzed on the gels. Total proteins were stained with
Coomassie Blue, and SRCL ligands were visualized by incubating blots with
125I-SRCL.
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common keratin contaminants as well as hemoglobin, which
probably bound to haptoglobin during preparation of the gran-
ulocyte extract and co-purifies on the affinity column. Neutro-
phil integrin 2, ICAM-3, and CEACAM-8 are known to carry
Lewisx epitopes (30–32). Although these proteins were not
identified using stringent search parameters, peptides from
these proteins would be hard to detect because of masking by
the abundant peptides from lactoferrin, which covers a similar
molecular weight range on the gel, and examination of the data
for unassigned peptides in this region revealed peptides attrib-
utable to integrin 2 and ICAM-3 in the appropriate molecular
weight bands. CEACAMwould be particularly difficult to iden-
tify from themass spectrometry data because the high degree of
glycosylation of this protein prevents matching of many of the
tryptic peptides. Therefore, a blot of fractions from the affinity
column was also probed with anti-CEACAM antibodies,
revealing that a proportion of CEACAM is also bound by the
column and eluted with EDTA (Fig. 2B). The presence of
CEACAM in the wash fractions indicates that only a subset of
CEACAM proteins carry the appropriate glycosylation to be
bound by SRCL.
The potential ligands for SRCL isolated by affinity chroma-
tography can be categorized into two groups as follows: cell
surface transmembrane glycoproteins, and soluble glycopro-
teins of secondary granules (Fig. 2C). The cell surface glycopro-
teins are also ligands for the Lewisx-binding C-type lectin DC-
SIGN, which also recognizes Lewisx-containing glycans (30, 33,
34), suggesting that DC-SIGN and SRCL may interact with
overlapping sets of neutrophil glycoproteins to mediate inter-
action of neutrophils with dendritic cells and endothelia,
respectively. However, the most abundant ligand for SRCL is
the soluble granule protein lactoferrin, and many of the addi-
tional SRCL ligands, includingMMP-8,MMP-9, and haptoglo-
bin, are also soluble proteins found in granules. These results
suggest that a distinct group of soluble glycoproteins contained
within secondary granules are major previously unidentified
carriers of Lewisx in neutrophils, explaining early reports of the
presence of CD15 epitopes on uncharacterized granule glyco-
proteins (35, 36).
The fact that themajority of the ligandmolecules for SRCL in
neutrophils are soluble granule glycoproteins rather than cell
surface glycoproteins suggests that rather than functioning
principally as an adhesion receptor, SRCL may have a role in
clearing soluble secondary granule glycoproteins that are
released by degranulation of neutrophils at sites of inflamma-
tion. Such a role would be consistent with the known endocytic
capability of the receptor (6) andwould complement that of the
macrophage mannose receptor, which clears myeloperoxidase
released from neutrophil primary granules (37). The Lewisx
structure would therefore act as a recognition tag added to a
range of soluble glycoproteins to facilitate their clearance fol-
lowing exocytosis.
FIGURE 2. Identification of SRCL ligands isolated from neutrophils. A, SDS-polyacrylamide gel of fractions from separation of granulocyte extracts on the
SRCL affinity column. The gel was stained with Coomassie Blue, and slices were subjected to proteomic analysis. Major proteins identified in each band are
indicated.Details of protein identification areprovided in supplemental Tables S1 andS2.B, confirmation that some formsofCEACAMare ligands for SRCL. Blot
of an SDS-polyacrylamide gel was probed with anti-CEACAM antibody, which was visualized with phosphatase-conjugated protein A. C, summary of ligands
identified by proteomics and blotting. The distribution of glycoproteins in granulocytes is shown for comparison.
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Fucose-dependent High Affinity Binding of Neutrophil Lacto-
ferrin to SRCL—The idea that SRCLmay serve to clear released
granule proteins tagged with Lewisx-containing glycans was
investigated further by examining the nature of the interaction
of SRCL with several granule glycoproteins. Following diges-
tion with bovine kidney -L-fucosidase, blots of granule glyco-
proteins show almost complete loss of reactivity with SRCL as
expected for fucose-dependent binding of SRCL to Lewisx
groups on these glycoproteins (Fig. 3). Fucose-dependent bind-
ing of SRCL to MMP-8 and MMP-9 in addition to lactoferrin
suggests that SRCL recognizes glycan structures common to a
range of neutrophil granule proteins and that lactoferrin can be
used as a model for this group of proteins.
A competition assay for binding to immobilized CRD
from SRCL, using LNFPIII-BSA as a reporter ligand, was
employed to obtain quantitative information about lactofer-
rin binding to SRCL. The KI of 6.1 M for lactoferrin is more
than 10-fold higher than the KI of 87 M for Lewisx (Fig. 4A).
The affinity of SRCL for lactoferrin was also measured using
surface plasmon resonance to monitor binding of the CRD
from SRCL to lactoferrin immobilized on a sensor chip sur-
face, which yielded a binding constant of 4.7 M (Fig. 4B).
Because the CRD of SRCL is monomeric, the binding
detected represents the interaction of one protein molecule
with one glycan. The similarity in the values in the competi-
tion and surface plasmon resonance experiments suggests
that lactoferrin binds to immobilized CRDs through a single
glycan at a time, possibly reflecting the disposition of the two
N-glycans on lactoferrin, which project from diametrically
opposite sides of the molecule. Although it is possible that
the enhanced binding to lactoferrin compared with the oli-
gosaccharide ligand could reflect some recognition of the
lactoferrin polypeptide by SRCL, it has been observed that
glycan-binding proteins often bind to glycoproteins with
higher affinity than to free glycans, even where the enhance-
ment cannot be due to multivalent effects or sequence-spe-
cific interactions with the polypeptide (38). The difference in
binding affinity between lactoferrin and Lewisx may there-
fore be due to presentation of the Lewisx structure on a
glycoprotein.
FIGURE 3. Fucose dependence of binding of SRCL to granule proteins. Samples of purified neutrophil lactoferrin and matrix metalloproteinase were
incubated in the presence or absence of fucosidase and separated on SDS-polyacrylamide gels that were stained with Coomassie Blue or blotted onto
nitrocellulose and probed with 125I-SRCL.
FIGURE 4. Quantitative analysis of SRCL binding to neutrophil lactoferrin. A, competition binding assay with immobilized CRD from SRCL probed
with 125I-LNFPIII-BSA in the presence of competing oligosaccharide or lactoferrin. Experimental data are shown as symbols and fitted curves for first order
binding are shown as solid lines. Data shown are averages of duplicates, and KI values represent the average  S.D. for two separate experiments.
B, binding analyzed by surface plasmon resonance. CRD from SRCL at varying concentrations was flowed over a sensor surface coated with neutrophil
lactoferrin.
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Modulation of SRCL Binding by Tissue-specific Glycosylation
of Lactoferrin—In addition to being found in neutrophil gran-
ules, lactoferrin secreted frommammary epithelial cells is pres-
ent in milk (39), making it possible to investigate cell type-spe-
cific differences in lactoferrin glycosylation. In a blotting
experiment, alkaline phosphatase-conjugated SRCL was far
more reactive toward neutrophil-derived lactoferrin than milk
lactoferrin (Fig. 5A), suggesting that the neutrophil protein car-
ries more Lewisx structures that are recognized by SRCL. Cor-
respondingly, a KI value for milk lactoferrin in the solid phase
competition binding assay could not be measured because suf-
ficiently high protein concentrations could not be achieved
(data not shown).
The basis for differential interaction of SRCLwith neutrophil
and milk lactoferrin was initially investigated by fractionation
of the lactoferrin samples on an SRCL affinity column (Fig. 5B).
Some neutrophil lactoferrin was washed off the column with
Ca2-containing buffer, but most was only released using
EDTA, indicating that the majority of neutrophil lactoferrin
molecules bind with high affinity to SRCL. In contrast, almost
all of the milk-derived protein was washed off the column with
Ca2-containing buffer, with only a very minor proportion
being eluted with EDTA, indicating that the majority of mole-
cules do not bind to SRCL or bind with low affinity. Although
SRCL does not bind to sialyl Lewisx structures (38), the possi-
bility that poor interaction with milk lactoferrin is due to cap-
ping with sialic acid was dismissed because neuraminidase
digestion does not affect the reactivity of SRCL with either the
milk or the neutrophil lactoferrin samples, indicating that few
sialyl-Lewisx groups are present in either sample (data not
shown).
Analysis of N-Glycans from Lactoferrin—Each of the two
lobes of human lactoferrin is glycosylated at a single asparagine
residue (40). It was previously reported that human neutrophil
lactoferrin glycans are homogeneous biantennary structures
with terminal sialic acid and the complete absence of fucose,
even from the core (41). The reported absence of fucose is sur-
prising, given the documented abundance of the Lewisx modi-
fication in neutrophils (42). The fucose dependence of SRCL
binding demonstrated here is in direct contradiction with this
report and indicates that the structures of neutrophil lactofer-
rin glycans need to be re-examined.
The glycomic profile of the permethylatedN-glycans on neu-
trophil lactoferrin was obtained fromMALDI-MS analysis (Fig.
6A). The deduced monosaccharide compositions for the major
peaks indicate that all the glycans have been processed to com-
plex type structures rather than remaining as high mannose or
hybrid structures (supplemental Table S3). Based on evidence
described in detail below, although a portion of the glycans have
a minimal bi-antennary HexNAc4Hex5 skeleton, many also
have additional N-acetyllactosamine units that either extend
the antennae or add additional branches up to tetra-antennary
N-glycans, and virtually all of the glycans are decorated with
Lewisx epitopes, either on different antennae as terminal
groups or as multiple Lewisx groups on the same antenna. Gly-
cans with more than one fucose residue carry at least a propor-
tion of outer arm fucose as part of a Lewisx epitope that could
mediate binding to SRCL.
An example ofMS/MS analysis of the secondmost abundant
glycan, HexNAc6Hex7Fuc3 (m/z 3490), is shown in Fig. 7. This
molecular ion corresponds mainly to a mixed population of
core-fucosylated tri-antennary structures with different
arrangements of Lewisx epitopes as shown by loss of both ter-
minal and extended Lewisx groups (m/z 2853, 2230, 2390, and
2404). The presence of the Lewisx epitopewas demonstrated by
the elimination of fucose from themolecular ion to generate the
m/z 3284 fragment, indicating that the fucose residue is linked
at the 3-position of GlcNAc. This result is consistent with pre-
vious evidence that the antennae on neutrophil glycans contain
fucose in the 1,3-linkage of the Lewisx epitope but not the
1,4-linkage of the Lewisa structure (43).
Consistent with many of the N-glycans being tri- and tetra-
antennary structures, gas chromatography-mass spectrometry
analysis indicated that of the total -mannose residues in the
pool of neutrophil lactoferrin glycans, 47% are 2-linked -man-
nose, 20% are 2,4-linked -mannose, and 32% are 2,6-linked
-mannose (supplemental Table S4). MS/MS fragmentation
spectra (supplemental Fig. S2) indicated that tri-antennary
forms predominate over the tetra-antennary structures and
that additionalN-acetyllactosamine units are distributed across
the antennae to give branches of similar length, rather than all
beingadded toa single antenna.MS/MSanalysisof glycans follow-
ing endo--galactosidase digestion (supplemental Fig. S3A) orHF
FIGURE 5. Differential binding of SRCL to milk and neutrophil lactoferrin. A, SDS-polyacrylamide gels of lactoferrin were stained with Coomassie Blue or
blotted onto nitrocellulose and probed with SRCL conjugated to alkaline phosphatase (SRCL-AP). B, comparison of fractionation of neutrophil and milk
lactoferrin on immobilized SRCL. Fractions from the affinity column were analyzed on SDS-polyacrylamide gels that were stained with Coomassie Blue.
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treatment (supplemental Fig. S4) confirms that both tri- and
tetra-antennary glycans are present.
MS analysis after endo--galactosidase digestion (supple-
mental Fig. S3A andTable S5) revealed structures that were not
affected by the enzyme, supporting the conclusion that neutro-
phil lactoferrin N-glycans frequently carry multiple Lewisx
groups attached on the same antenna, in which the internal
fucose residues block the action of the enzyme. Analysis of frag-
ments released by endo--galactosidase digestion (supplemen-
tal Fig. S3B) also showed the presence of large amounts of
Lewisx-containing tetrasaccharide (m/z 896), indicating that
terminal Lewisx groups are abundant. The absence of
GlcNAc1–3Gal oligosaccharides at m/z 518 also shows that
there are no long N-acetyllactosamine extensions that do not
bear fucose residues. Finally, release of fucose by HF treatment
indicated that around 80% of glycans are core-fucosylated (sup-
plemental Fig. S4 and Table S6).
Sialylated structures were detected only as a minor fraction
of neutrophil lactoferrin oligosaccharides (m/z 3402, 4924, and
5098; Fig. 6A). Gas chromatography-mass spectrometry link-
age analysis on untreated and desialylated neutrophil lactofer-
rin N-glycans revealed that both 2,3- and 2,6-linked sialic
acids are present, with 58% of sialic acid in the 2,6-linkage
(supplemental Table S7). In sialylated glycans, the sialic acid
and fucose residues are always found on separate antennae, so
that the sialyl Lewisx epitope is not observed (supplemental Fig.
S2, D and H).
The MALDI-MS glycomic profile of milk lactoferrin N-gly-
cans is considerably simpler than that of the neutrophil protein
(Fig. 6B). The glycans are also of generally smaller size than
those from neutrophil lactoferrin, reflecting the fact that milk
lactoferrin glycans are predominantly without additional
N-acetyllactosamine units added to the basic core (supplemen-
tal Table S8). Unlike theN-glycans of neutrophil lactoferrin, the
most abundant glycans frommilk lactoferrin have one antenna
capped with sialic acid, which has previously been found to be
exclusively in 2–6-linkage (44). MS/MS analysis indicated
that the low abundancemilk lactoferrin glycans that have addi-
FIGURE6.AnalysisofpermethylatedN-linkedglycans fromlactoferrinbyMALDI-TOFmassspectrometry.A,glycans released fromneutrophil lactoferrin.
B,glycans released frommilk lactoferrin. Spectra for the50%acetonitrile fraction followingC18 Sep-Pak fractionationare shown. Putative structuresof themost
abundant species present in each fraction, deduced from composition, MS/MS analysis, endoglycosidase digestion, linkage analysis, and information of
biosynthetic pathways, are shown schematically. Structures that show sugars outside a bracket have not been unequivocally defined. All molecular ions are
[M Na].
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tional N-acetyllactosamine units are biantennary rather than
tri- or tetra-antennary and that sialic acid is present only on the
unextended antenna (supplemental Fig. S5,G–J), in agreement
with previous studies (44, 45). In addition, the milk lactoferrin
glycans contain outer arm fucose (supplemental Fig. S5), which
has previously been reported to be 1,3-linked to form Lewisx
(44). The MS/MS indicates that sialic acid and fucose residues
are always found on separate antennae, so that the sialyl-Lewisx
epitope is not observed (supplemental Fig. S5). Unlike neutro-
phil lactoferrin, milk lactoferrin contains Lewisy structures
(supplemental Fig. S5, F and J), consistent with the expression
of1,2-fucosyltransferase in epithelial cells but not neutrophils
(46).
The much reduced abundance of terminal Lewisx groups in
milk lactoferrin and the absence of clusters of this epitope com-
paredwith neutrophil lactoferrin is consistent with the reduced
affinity of the milk form of the protein for SRCL. High affinity
binding leading to retention of proteins on the SRCL column
probably requires multivalent interaction of multiple Lewisx
groups, either on separate glycans or on different branches of a
single glycan. Almost every neutrophil lactoferrin molecule
carries multiple Lewisx groups per molecule and is thus tightly
retained, whereas milk lactoferrin molecules carry on average
at most a single Lewisx group, which is insufficient to cause
retention on the SRCL column.
Abundance of High Affinity Ligands for SRCL in Neutrophil
Lactoferrin—To establish a specific correlation between the
abundance of Lewisx epitopes on neutrophil lactoferrin and the
interactionwith SRCL, lactoferrin was fractionated based on its
affinity for the SRCL affinity column and glycans associated
with each fractionwere analyzed (Fig. 8A). The small fraction of
lactoferrinmolecules that did not bind to the column, or bound
weakly, were washed off with buffer containing Ca2, whereas
lactoferrin molecules that bound strongly were eluted with
EDTA. The molecules were re-applied to the column in the
presence of Ca2 and again eluted with EDTA. This strategy
ensures that at least one of the glycans on the bound population
of lactoferrin binds tightly to SRCL, although these molecules
may bear a second glycan that is not a high affinity ligand, so the
pool of glycans released from the binding fraction is enriched
for high affinity ligands but does not consist exclusively of high
affinity ligands.
Themolecular ion profiles obtained for the binding and non-
binding pools of glycans are strikingly different, particularly in
the region of the spectrum above m/z 3400, which includes
several major peaks for the binding sample but only a very
minor fraction of the glycans in the nonbinding sample (Fig.
8B). Comparing the glycan compositions found in the two sam-
ples shows that the extent to which a glycan is retained on the
SRCL column depends strongly on the number of fucose resi-
dues in the structure (Fig. 8C and supplemental Tables S9 and
S10). Glycans with only one fucose residue are for themost part
found in the nonbinding fraction, because this single fucose is
usually attached to the core GlcNAc residue and is not part of a
Lewisx group. In contrast, glycans with three or more fucose
residues, generally corresponding to two or more outer arm
fucose residues, were found almost exclusively in the binding
fraction. Glycans with two fucose residues, one of which is usu-
ally on an outer arm, were found in both fractions. Thus, the
presence of more than one Lewisx group on a glycan signifi-
cantly enhances binding to SRCL andmay be sufficient to cause
retention of the proteinmolecule even if the glycan at the other
position does not carry any Lewisx. The isolation of a lactoferrin
fraction that does not bind to SRCL served to enrich rare gly-
cans that were not discernable in the molecular ion profile of
total neutrophil lactoferrin glycans (supplemental Table S9),
including a biantennary glycan in which both antennae are
capped with sialic acid, which is common in serum glycopro-
FIGURE 7. Fragmentation of an abundant neutrophil glycan. The [M Na]molecular ion at m/z 3490 from Fig. 6A was subjected to MS/MS analysis to
demonstrate the presence ofmultiple fucose residues on outer arms of a tri-antennary oligosaccharide. The horizontal arrows on the spectrum indicate losses
from the molecular ion [M Na] of the designated sequences in the inset. The signal atm/z 3039 corresponds to loss of HexNAcFuc from the reducing side
of the glycans, indicative of core fucosylation, and the ion atm/z 3284 results from elimination of a fucose residue in a Lewisx epitope. The ions atm/z 486 and
660 establish the presence of a terminal N-acetyllactosamine unit and a terminal Lewisx terminal epitope, whereas the ions atm/z 1109 and 1283 correspond
to single elongated and double Lewisx epitopes.
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teins but very rare in neutrophil lactoferrin. The results provide
strong evidence that the efficient binding of neutrophil lacto-
ferrin to SRCL results from the enrichment in glycans bearing
multiple terminal Lewisx epitopes.
Internalization of Neutrophil Lactoferrin Mediated by SRCL—
Uptake of Lewisx-bearing ligands mediated by SRCL was
visualized directly by incubating fluorescein-labeled glycopro-
tein with SRCL-transfected fibroblasts and detected with
anti-fluorescein antibody followed by fluorescently labeled sec-
ondary antibody. The assay was validated using the neoglyco-
protein LNFPIII-BSA, which associates with SRCL-transfected
fibroblasts within 5 min and accumulates in intracellular com-
partments over an hour (Fig. 9A). Fluorescein-labeled BSA that
does not carry Lewisx groups is not internalized. These results
are consistentwith earlier indirect studies based ondetection of
released degradation products in the medium following uptake
of LNFPIII-BSA by SRCL-transfected fibroblasts (6). When
similar ligand uptake experiments were performed with neu-
trophil lactoferrin, internalization of fluorescein-tagged lacto-
ferrin was readily observed in the SRCL-transfected fibroblasts
(Fig. 9B). The specificity of the uptake observed was confirmed
by the finding that fluorescein-tagged ovalbumin, which carries
high mannose and hybrid N-glycans without Lewisx groups,
was not bound and internalized. The demonstration that SRCL
canmediate internalization of neutrophil granule glycoproteins
is consistent with the proposal that the receptor clears such
glycoproteins at sites of inflammation.
BroadDistribution of SRCL in Endothelial Cells—Expression
of SRCL has previously been characterized in human umbilical
vein endothelial cells and in a subset of endothelia, but efficient
local clearancewould require a broad distribution of SRCLnear
potential sites of glycoprotein release. A survey of the distribu-
tion of SRCL in a panel of cDNA libraries confirmed that the
receptor is expressed, at varying levels, in all tissues examined,
FIGURE 8. Comparison of neutrophil lactoferrin samples with high and low affinity for SRCL. A, SDS-polyacrylamide gel analysis of neutrophil lactoferrin
fractionated by two rounds of affinity chromatography on immobilized SRCL. Gels were stainedwith Coomassie Blue, and the indicated fractionswere pooled
for glycan analysis. B,mass spectrometry of glycans in binding and nonbinding fractions. Species unique to each pool are highlighted in yellow. C, summary of
major glycans present in binding and nonbinding fractions, based on data in B and additionalMS/MS results (data not shown), with Lewisx groups highlighted
in green.
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including a range of cardiovascular tissues not previously
examined (Fig. 10A). A follow-up study using immunohisto-
chemistry to examine SRCL localization revealed that SRCL is
expressed throughout the vasculature in arteries, arterioles,
veins, venules, and continuous capillaries (Fig. 10B). In most
tissues the expression is confined to endothelial cells. Com-
bined with earlier reports of SRCL expression patterns, these
results are consistent with the idea that SRCL is widely
expressed in endothelia.
DISCUSSION
The results presented here suggest a role for SRCL in scav-
enging for glycoproteins released by degranulation of neu-
trophils in inflamed tissues. SRCL expressed on endothelial
cells could clear neutrophil granule glycoproteins through
multiple routes (Fig. 11). Because of the localization of SRCL
throughout the vasculature, released granule glycoproteins
could be cleared locally from the tissue surrounding the
blood vessel by SRCL molecules expressed on the surface of
the endothelial cell. In addition, glycoprotein could be
cleared systemically following either direct release into the
bloodstream or following diffusion into the bloodstream
after release in subendothelial tissues. In either case, clear-
ance of potentially destructive enzymes and immunomodu-
latory factors such as the matrix metalloproteinases and
lactoferrin would have a protective effect.
Analysis of the N-glycans of neutrophil lactoferrin by mass
spectrometry revealed a range of large and highly fucosylated
structures. Despite considerable heterogeneity in the num-
ber and positioning of additional N-acetyllactosamine units
and of fucose residues, the vast majority of the glycans carry
Lewisx groups, often on multiple antennae. The glycan skel-
eton thus serves as a scaffold for the display of Lewisx groups,
which are recognized by SRCL. The display of Lewisx struc-
tures on multiple similarly sized antennae appears to repre-
sent the optimum disposition of carbohydrate groups for
binding to SRCL, because such glycans bind to the receptor
with higher affinity than small glycans with only one Lewisx
group as found onmilk lactoferrin. Tagging of a glycoprotein
with multiple copies of a receptor-targeting epitope is essen-
tial in the case of clearance receptors, because this allows
them to achieve multivalent ligand binding to a soluble gly-
coprotein ligand. This arrangement contrasts with that
found in PSGL-1, the ligand for the C-type lectin P-selectin,
which displays a single sialyl-Lewisx group on one extended
O-glycan antenna. This alternative arrangement of glycan
ligands is effective for cell adhesion, because multiple copies
of the receptor and ligand can interact when two cell surfaces
come into contact (47).
The abundance of Lewisx groups in neutrophil glycoproteins
is likely to be due to expression of the 1,3-fucosyltransferase
FUT9, which is particularly selective for synthesis of this struc-
ture and is responsible for addition of Lewisx epitopes to neu-
trophil cell surface proteins (33, 48, 49). A recent study showed
that SRCL recognizes CEACAM-1 expressed in transfected
cells only when cells are also transfected with FUT9, as well as
confirming the recognition by SRCL of proteins in a blot of
FIGURE 9. Internalization of glycoproteins by transfected fibroblasts expressing SRCL. A, neoglycoprotein LNFPIII-BSA and control BSA ligands. B, neu-
trophil lactoferrin and ovalbumin ligands. Cells were incubated for the indicated times at 37 °C with fluorescein-labeled glycoproteins. After fixation, bound
and internalized glycoproteinswere visualizedwith antibodies to fluorescein followedbyAlexa 488-labeled secondary antibodies. Nuclei were visualizedwith
DAPI stain. Bar, 20 m.
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neutrophil extract (50). Expression of FUT9 is limited to a small
number of cell types, including granulocytes, neurons, and an
unidentified cell type in the kidney (48, 51), indicating that the
synthesis of Lewisx may be regulated to enable its use as a spe-
cific recognition tag. Because neutrophil secondary granule
proteins are all synthesized during the samephase of neutrophil
development (52, 53), they are all exposed to the same reper-
toire of glycosylation enzymes and could be expected to receive
similar glycosylation to lactoferrin. The distinct carbohy-
drate recognition events mediated by the selectins and SRCL
are made possible by the different pathways of synthesis of
the sialyl-Lewisx and Lewisx epitopes from terminal type II
N-acetyllactosamine units as follows: sialyl Lewisx is formed by
the sequential actions of sialyltransferase ST3GalIV and fuco-
syltransferase FUT7 (47), and Lewisx is formed by the action of
FUT9 and is farmore abundant (42). The substrate selectivity of
the enzymes involved in the synthesis of these structures is
matched by the selectivity of glycan recognition in the cognate
receptors (6, 54).
The functions of the Lewisx structure in neutrophils and
other cells have remained unclear even though the epitope
has been known for many years. The finding that the Lewisx
epitope is used as a recognition tag may reflect the fact that it
is an optimal structure for recognition by glycan-binding
proteins because it is an accessible terminal structure that
adopts a single fixed conformation whether it is free in solu-
tion or bound to a protein (55), so there is little entropy
penalty for binding. This arrangement is advantageous
because glycan-binding proteins typically make only limited
contacts with a bound glycan (56). A role for Lewisx in medi-
ating communication between neutrophils and dendritic
cells through binding to the glycan-binding receptor DC-
SIGN has been proposed (57). The work presented here is
consistent with a function for Lewisx in mediating protein
FIGURE 10. Tissue distribution of SRCL expression. A, PCR analysis of the tissue distribution of SRCL. A fragment of 492 bases, covering the CRD-encoding
region, was amplified for 35 cycles. Control amplification of the cDNA for glyceraldehyde-3-hydrogenase (GAPDH) for 25 cycles was performed in parallel.
B, immunohistochemical localization of SRCL in tissues using rabbit polyclonal antibodies raised against the CRD of SRCL, counterstained with peroxidase-
conjugated goat anti rabbit antibody, followed by tyramide treatment and incubation with Alexa 488-labeled streptavidin. Nuclei were visualized with DAPI
stain. A summary of all tissues examined is provided in supplemental Table S11. Arrows highlight examples of endothelia, and bars indicate 50 m.
FIGURE 11. Summary diagram showing potential modes of neutrophil
granule glycoprotein clearance by SRCL on endothelial cells. Possible
routes of uptake include the following: 1) removal from the luminal surface of
the cell following release of granule proteins from circulating neutrophils; 2)
removal from the luminal surface following release in tissue and leaking back
in the lumen; or 3) uptake from the tissue following local release.
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clearance through interaction with SRCL, suggesting that
the Lewisx tag may have multiple functions resulting from
binding to different receptors in different cell types.
It is proposed that SRCL functions as a distributed clearance
system, found throughout the vasculature, capable of picking
up glycoproteins locally as well as from the circulation. This
arrangement contrasts with the asialoglycoprotein receptor,
which represents a centralized system for clearance of circulat-
ing glycoproteins into the liver. The SRCL arrangement is
somewhat more reminiscent of the macrophage mannose
receptor, which is able to scavenge locally released glycopro-
teins as well as glycoproteins in serum. However, for the man-
nose receptor this diversity in function is a result of expression
on both tissue macrophages and sinusoidal endothelial cells in
the liver, although SRCL could function in both roles through
expression on a single cell type. Future studies with mice lack-
ing the murine homolog of SRCL will provide a useful in vivo
complement to the biochemical and cell biological character-
ization presented here.
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